# BI-1607

Source: https://onco.cc/drugs/bi-1607/  
OnCo record `bi-1607` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BI-1607 is an experimental monoclonal antibody from BioInvent International, in phase 2 trials for melanoma, uveal melanoma and HER2-positive breast cancer and other cancers.

## Summary

BI-1607 is a monoclonal antibody (engineered) from BioInvent International. An engineered anti-FcγRIIB (FCGR2B) antibody intended to enhance efficacy and overcome resistance to existing cancer treatments such as targeted antibodies and checkpoint inhibitors; tested with ipilimumab and pembrolizumab in melanoma and earlier with trastuzumab. Its furthest stage is phase 2, for melanoma, uveal melanoma, HER2-positive breast cancer and HER2-positive gastric cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1b/2a NCT06784648 (melanoma, with ipilimumab and pembrolizumab) active, not recruiting; the earlier trastuzumab combination trial NCT05555251 is terminated (registry, checked 3 Nov 2026). The BI-1607 page is no longer linked from BioInvent's programme menu. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: BI-1607
- Modality: Monoclonal antibody (engineered)
- Mechanism: An engineered anti-FcγRIIB (FCGR2B) antibody intended to enhance efficacy and overcome resistance to existing cancer treatments such as targeted antibodies and checkpoint inhibitors; tested with ipilimumab and pembrolizumab in melanoma and earlier with trastuzumab.

## Sources

- BioInvent International: bioinvent.com: https://www.bioinvent.com/en/clinical-programs/our-programs/bi-1607
- BioInvent International: bioinvent.com: https://www.bioinvent.com/en
- ClinicalTrials.gov: trials of BI-1607: https://clinicaltrials.gov/search?intr=BI-1607

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [HER2-positive gastric cancer](https://onco.cc/cancers/gastric-her2-positive/), [Melanoma](https://onco.cc/cancers/melanoma/), [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- targets: [FCGR2B](https://onco.cc/targets/fcgr2b/)
- companies: [BioInvent International](https://onco.cc/companies/bioinvent-international/)
- trials: [BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors](https://onco.cc/trials/nct05555251/), [Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma](https://onco.cc/trials/nct06784648/)

---
JSON: https://onco.cc/api/v1/entities/bi-1607.json